Investigating how a specific protein complex affects breast cancer progression
Role of the CTLH E3 ubiquitin ligase in breast cancer progression
This study is looking at how a specific protein complex affects the growth of HER2-positive breast cancers, which can be tough to treat, and aims to find new ways to make treatments work better for patients like you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Iowa NIH-funded |
| Lab location | 1 site (Iowa City, United States) |
| Project ID | NIH-11052532 on NIH RePORTER |
What this research studies
This research focuses on HER2-positive breast cancers, which are known for their aggressive nature and poor prognosis. The team aims to understand how a protein complex called the CTLH E3 ubiquitin ligase influences the progression of these cancers, particularly in relation to drug resistance against HER2-targeted therapies. By studying the signaling pathways involved, the researchers hope to identify new therapeutic targets that could enhance treatment effectiveness. Patients may benefit from insights that could lead to improved strategies for managing HER2-positive breast cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with HER2-positive breast cancer who may be experiencing challenges with current therapies.
Not a fit: Patients with non-HER2-positive breast cancer or those who are not currently undergoing treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with HER2-positive breast cancer, potentially overcoming current drug resistance issues.
How similar studies have performed: Previous research has shown promise in targeting G protein coupled receptors in cancer treatment, suggesting that this approach may yield beneficial results.
Where this research is happening
Iowa City, United States
- University of Iowa — Iowa City, United States (Active)
Researchers
- Principal investigator: Chen, Songhai — University of Iowa
- Study coordinator: Chen, Songhai
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.